clinical trial · NCT07110584
Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors
ModeX Therapeutics, An OPKO Health Company·phase2·recruiting·n = 235
Advanced TumorsMDX2004
brief summary
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2004 in patients with advanced tumors.
started
Oct 1, 2025
primary completion
Jun 30, 2031
completion
Jun 30, 2031
last updated
Mar 5, 2026
official title
A Phase 1/2, Multi-Center, Open-Label Clinical Study Evaluating MDX2004 In Participants With Advanced Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol